NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD) - Get Report were gaining in early afternoon trading on Friday as Citigroup said sales of the company's hepatitis C products could improve due to contributions from new treatments, Barron's reports.
Gilead's hepatitis C sales are still below consensus, Citi notes, but the franchise "is seeing some uptick in the last six to seven weeks as new starts are tracking slightly better than the beginning of the quarter."
New start sales in the month of September so far are up by 3% over August sales, Citi said, citing IMS Health data.
Third quarter sales for the company's hepatitis C prescriptions are tracking toward $1.78 billion to $1.85 billion, according to Citi. Consensus is looking for $2.13 billion in hepatitis C sales, the firm added.
Gilead Sciences is a Foster City, CA-based biopharmaceuticals company focusing on HIV, and hepatitis B and C products.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rated this stock as a "buy" with a ratings score of B.
The company's strengths can be seen in multiple areas, such as its notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income.
You can view the full analysis from the report here: GILD